Search Result

Your Search for:Pharmacy Online ⭐ www.pills2sale.com ⭐ Buy Viagra Online In Pakistan - Where To Buy Viagra In Toronto


Analyst Coverage

…BofA MERRILL LYNCH Dr. Alec W. Stranahan+1 646 743 2109 alec.stranahan@bofa.com Dr. Geoff Meacham+1 646 855 1004 geoff.meacham@bofa.com BLOOMBERG Cinney Zhangczhang429@bloomberg.net Sam Fazelimfazeli@bloomberg.net CANACCORD GENUITY Dr. John Newman+1…


Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi‑med.com.   Tagrisso® and Iressa® are trademarks of the AstraZeneca PLC group of companies.   Forward‑Looking…


CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

www.ckh.com.hk   About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 470 scientists and…


CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

…months ended 30 June 2019 respectively. For more information, please visit www.ckh.com.hk About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products….


Dual-listing FAQs

www.londonstockexchange.com. What is Nasdaq? The Nasdaq Stock Market, also known as simply Nasdaq, is an American stock exchange. It is the second-largest stock exchange by market capitalization in the world,…


Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

…presentation will be available at www.chi-med.com.   Surufatinib Phase I/Ib study in the US Safety and tolerability data of surufatinib in western patients were presented at ESMO 2019 as a…


Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

…availability to ordinary people and enhance the quality of the patients’ lives. For more information, please visit: www.innoventbio.com.   About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which…


Notice of Extraordinary General Meeting and Shareholders’ Circular

…For more information, please visit: www.chi-med.com. FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of…


Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification

…drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   About AstraZeneca…


2019 Annual Report and Notice of Annual General Meeting

…a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com….


Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares

…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions…


Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

www.chi-med.com. About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff…


Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

…a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com….


Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference

…Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:00pm PST in San Francisco, CA. The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder…


Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

…Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   Information about the Offering The Offering is being made pursuant to a shelf registration statement on…


Chi-Med to Announce 2019 Final Results

…Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 Annie Cheng, Vice President, Corporate…


Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

…of these adverse effects is feasible. For important safety information about fruquintinib, please see www.chi-med.com.   About Other Fruquintinib Development Programs Global Development Phase I monotherapy in the U.S.: In…


Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

…Global Select Market. For more information, please visit: www.chi-med.com.   Information about the Offering The Offering is being made pursuant to a shelf registration statement on Form F-3 filed by…


Chi-Med to Attend Upcoming Investor and Industry Conferences

…at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.”   About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical…


Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

…London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121…


Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

…more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act…


Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

…Select Market. For more information, please visit: www.chi-med.com.     Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private…


Chi-Med to Announce 2019 Half-Year Financial Results

…visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786…


Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

…hand-foot syndrome and proteinuria. Clinically effective management of these adverse effects is feasible. For important safety information about fruquintinib, please see www.chi-med.com. About Chi-Med Chi-Med (AIM/Nasdaq: HCM) is an innovative…


Disclosure Update

…is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking…


Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

…Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries…


Chi-Med to Announce 2018 Final Results

…Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee,…


Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

…Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30am PST in San Francisco, CA. The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder…


Chi-Med Announces Proposed Public Offering of ADSs

…visit: www.chi-med.com.   Information about the Offering The Offering will be made pursuant to a shelf registration statement on Form F-3 filed by Chi-Med with the United States Securities and…


Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

…China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the…


Chi-Med Announces US$100 Million Equity Investment by General Atlantic

…the website: www.generalatlantic.com.   About Chi-Med Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and…


Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

…in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within…


Hutchison China MediTech Limited Announces Exercise of Overallotment Option

…at prospectus.cpdg@db.com. This announcement does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale…


Chi-Med Announces Proposed Offering of ADSs (RNS)

…products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   Forward-Looking Statements This announcement contains forward-looking…


Chi-Med Announces Proposed Offering of ADSs

…distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. Forward-Looking…


Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

…drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   About AstraZeneca…


Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

…Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of…


Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

…visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking…


Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

…health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release…


Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

…see www.chi-med.com. About Fruquintinib Development in CRC in China Clinical development of fruquintinib began in 2011 with an initial Phase I trial in 40 solid tumor patients, followed by a…


Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786 David…


Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program

…Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new…


Chi-Med Announces Secondary Offering of American Depositary Shares

www.chi-med.com.   Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements…


Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.   About Inmagene Biopharmaceuticals Inmagene, with wholly owned subsidiaries in Shanghai, San Diego, and Hangzhou, is…


Chi-Med Announces US$100 Million Equity Investment by CPP Investments

…real estate, infrastructure and fixed income are made by CPP Investments. Headquartered in Toronto, with offices in Hong Kong, London, Luxembourg, Mumbai, New York City, San Francisco, São Paulo and…


Warning to Shareholders

…to see if the firm is authorized by FCA. Report the call to the FCA by calling the FCA Consumer Helpline on 0800 111 6768 or complete the online boiler…


Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

…(SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. Lancet Oncol. 2020; S1470-2045(20)30496-4. DOI: 10.1016/S1470-2045(20)30496-4. [3] According to Frost & Sullivan. In 2018,…


Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

…placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. Lancet Oncol. 2020; S1470-2045(20)30496-4. DOI: 10.1016/S1470-2045(20)30496-4. [5] Xu J, Shen L, Bai C, et al. Surufatinib in advanced…


Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

…access to treatment options. [4] Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead…


Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering

…can be found on the SEHK’s website at www.hkex.com.hk/Listing/Getting-Started/Listing-on-the-Main-Board. The Company’s listing application and the Offering is subject to, among other things, the completion of the review process of the…


Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

…For more information, please visit: www.chi-med.com.   Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act…


Chi-Med Announces the Full Exercise of Underwriters’ Over-allotment Option

…more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995….


Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

…and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   Tagrisso® and Iressa®…


Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

…For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform…


Chi-Med to Announce 2018 Half-Year Financial Results

…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121…


Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

…multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor”…


Chi-Med to Attend Upcoming Investor Conferences

…be accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to…


Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

…of China. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities…


Chi-Med to Announce 2020 Half-Year Financial Results

…in its home market of China. For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President +852 2121 8200 Annie Cheng, Vice President +1 (973)…


Notification of Dilution of Voting Rights

…ended 31 December 2019. For more information, please visit www.ckh.com.hk.   About Chi-Med Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery…


Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

…candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.   About Lilly Lilly is a…


Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

…drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark…


Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

…Summit held from November 18 to 20, 2020; and The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020. Further information are available at www.chi-med.com in…


Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

…webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before…


Chi-Med to Announce 2020 Final Results

…the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President +852 2121 8200…


Chi-Med to Announce 2017 Final Results

…CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 U.K. &…


Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

…prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 1). For more information, please visit: www.chi-med.com….


2017 Annual Report and Notice of Annual General Meeting

…information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 U.K. & International Media Enquiries Anthony Carlisle, Citigate Dewe Rogerson +44…


Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

…accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to download…


Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements…


Total Voting Rights

…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS Investor…


Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

…the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the…


Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

…Select Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward ‑looking statements within the meaning of the “safe harbor ” provisions of the U.S….


Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

…more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act…


Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

…London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe…


Total Voting Rights

…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS Investor…


Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

…AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance…


Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

…is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Iressa® is a trademark of the AstraZeneca PLC group of companies….


Blocklisting Six Monthly Return

…multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.   CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200…


Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

…Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com….


Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

…visit: www.chi-med.com.   Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking…


Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

…Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation…


Total Voting Rights

…headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS…


Blocklisting Six Monthly Return

…headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS…


Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

…Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This…


Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

…majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of…


Total Voting Rights

…1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David Dible, Citigate Dewe Rogerson +44 7967 566…


Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

…the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.   Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor”…


Total Voting Rights

…1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David Dible, Citigate Dewe Rogerson +44 7967 566…


Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

…more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995….


Blocklisting Six Monthly Return

…multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com. CONTACTS Investor Enquiries Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200 David…


Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium

…Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.   Forward-Looking Statements…


Grant of Share Options under Share Option Scheme

…Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com. Forward-Looking Statements This announcement contains…


Total Voting Rights

…in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   CONTACTS Investor…


Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

…London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe…


Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

…information, please visit: www.chi-med.com.   Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of…


Grant of Share Options under Share Option Scheme

…please visit: www.chi-med.com.   Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking…


Block Admission Applications and Total Voting Rights

…visit: www.chi-med.com. Forward Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements…


Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

…1). For more information, please visit: www.chi-med.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform…


Grant of Share Options under Share Option Scheme

…Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.     Forward-Looking Statements…